Investors focused on the Medical space have likely heard of ASLAN Pharmaceuticals (ASLN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ASLN and the rest of the Medical group's stocks.
ASLAN Pharmaceuticals is a member of our Medical group, which includes 905 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ASLN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ASLN's full-year earnings has moved 26.61% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ASLN has moved about 7.39% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0.32%. This means that ASLAN Pharmaceuticals is outperforming the sector as a whole this year.
Looking more specifically, ASLN belongs to the Medical - Biomedical and Genetics industry, which includes 387 individual stocks and currently sits at #88 in the Zacks Industry Rank. This group has lost an average of 2.69% so far this year, so ASLN is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to ASLN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of ASLAN Pharmaceuticals (ASLN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ASLN and the rest of the Medical group's stocks.
ASLAN Pharmaceuticals is a member of our Medical group, which includes 905 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ASLN is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ASLN's full-year earnings has moved 26.61% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ASLN has moved about 7.39% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0.32%. This means that ASLAN Pharmaceuticals is outperforming the sector as a whole this year.
Looking more specifically, ASLN belongs to the Medical - Biomedical and Genetics industry, which includes 387 individual stocks and currently sits at #88 in the Zacks Industry Rank. This group has lost an average of 2.69% so far this year, so ASLN is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to ASLN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ASLN - FREE